Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Changes in length of time between the onset and cessation of painful migraine symptoms (migraine period) from the baseline. Safety evaluations conducted throughout the study.
Proportion of patients responding to the treatment. Changes from baseline to double-blind phase in number of monthly migraine attacks, monthly migraine days, number of days/month requiring rescue medication, and Health-Related Quality of Life measures.
12 Years to 65 Years (Child, Adult)
October 12, 2005
November 17, 2010
† Study has passed its completion date and status has not been verified in more than two years.